Literature DB >> 18522302

Invasive pneumococcal disease in Australia, 2006.

Paul W Roche1, Vicki Krause, Heather Cook, Jenny Barralet, David Coleman, Amy Sweeny, James Fielding, Carolien Giele, Robin Gilmour, Ros Holland, Riemke Kampen, Mitchell Brown, Lyn Gilbert, Geoff Hogg, Denise Murphy.   

Abstract

Enhanced surveillance for invasive pneumococcal disease (IPD) was carried out in all Australian states and territories in 2006 with comprehensive comparative data available since 2002. There were 1,445 cases of IPD notified to the National Notifiable Diseases Surveillance System in Australia in 2006; a notification rate of 7 cases per 100,000 population. The rates varied between states and territories and by geographical region with the highest rates in the Northern Territory, the jurisdiction with the largest proportion of Indigenous people. Invasive pneumococcal disease was reported most frequently in those aged 85 years or over (30.8 cases per 100,000 population) and in children aged one year (26.5 cases per 100,000 population). There were 130 deaths attributed to IPD resulting in an overall case fatality rate of 9%. The overall rate of IPD in Indigenous Australians was 4.3 times the rate in non-indigenous Australians. The rate of IPD in the under two years population continued to fall in 2006, but the rate in Indigenous children (73 cases per 100,000 population) was significantly greater than in non-Indigenous children (21 cases per 100,000 population). The rates of disease caused by serotypes in the 7-valent pneumococcal conjugate vaccine (7vPCV) decreased between 2002 and 2006 by 78% in children aged under two years as a result of the introduction of a universal childhood 7vPCV immunisation program. Significant decreases in IPD caused by 7vPCV serotypes also occurred in the 2-14 years and 65 years or over age groups. Rates of disease caused by non-7vPCV in the same periods were little changed. Serotypes were identified in 94% of all notified cases, with 43% of disease caused by serotypes in the 7vPCV and 85% caused by serotypes in the 23-valent polysaccharide pneumococcal vaccine (23vPPV). The number of invasive pneumococcal isolates with reduced penicillin susceptibility remains low and reduced susceptibility to third generation cephalosporins is rare.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18522302

Source DB:  PubMed          Journal:  Commun Dis Intell Q Rep        ISSN: 1447-4514


  26 in total

1.  Contribution of serotype and genetic background to virulence of serotype 3 and serogroup 11 pneumococcal isolates.

Authors:  Lauren J McAllister; Abiodun D Ogunniyi; Uwe H Stroeher; Amanda J Leach; James C Paton
Journal:  Infect Immun       Date:  2011-09-19       Impact factor: 3.441

2.  Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany.

Authors:  Alexander Kuhlmann; J-Matthias Graf von der Schulenburg
Journal:  Eur J Health Econ       Date:  2016-02-23

3.  Invasive pneumococcal disease in New South Wales, Australia: reporting Aboriginal and Torres Strait Islander status improves epidemiology.

Authors:  Peter D Massey; Kerry Todd; Maggi Osbourn; Kylie Taylor; David N Durrheim
Journal:  Western Pac Surveill Response J       Date:  2011-07-25

4.  Update on the success of the pneumococcal conjugate vaccine.

Authors:  Jd Kellner
Journal:  Paediatr Child Health       Date:  2011-04       Impact factor: 2.253

5.  Serotypes of Streptococcus pneumoniae isolates from children with invasive pneumococcal disease in Turkey: baseline evaluation of the introduction of the pneumococcal conjugate vaccine nationwide.

Authors:  Mehmet Ceyhan; Nezahat Gurler; Akgun Yaman; Candan Ozturk; Lutfiye Oksuz; Sengul Ozkan; Melike Keser; Nuran Salman; Emre Alhan; Duygu Esel; Meral Gultekin; Yildiz Camcioglu; Mustafa Gul; Yelda Sorguc; Sohret Aydemir; Murat Gunaydin; Yusuf Yakupogullari; Ahmet Kizirgil
Journal:  Clin Vaccine Immunol       Date:  2011-04-20

6.  Effects of pneumococcal conjugate vaccine 2 years after its introduction, the Netherlands.

Authors:  Gerwin D Rodenburg; Sabine C de Greeff; Angelique G C S Jansen; Hester E de Melker; Leo M Schouls; Eelko Hak; Lodewijk Spanjaard; Elisabeth A M Sanders; Arie van der Ende
Journal:  Emerg Infect Dis       Date:  2010-05       Impact factor: 6.883

7.  Epidemiology of nasopharyngeal carriage of respiratory bacterial pathogens in children and adults: cross-sectional surveys in a population with high rates of pneumococcal disease.

Authors:  Grant A Mackenzie; Amanda J Leach; Jonathan R Carapetis; Janelle Fisher; Peter S Morris
Journal:  BMC Infect Dis       Date:  2010-10-23       Impact factor: 3.090

8.  Streptococcus pneumoniae meningitis in Alberta pre- and postintroduction of the 7-valent pneumococcal conjugate vaccine.

Authors:  Jennie Johnstone; Gregory J Tyrrell; Thomas J Marrie; Sipi Garg; James D Kellner
Journal:  Can J Infect Dis Med Microbiol       Date:  2011       Impact factor: 2.471

9.  Potential cost-effectiveness and benefit-cost ratios of adult pneumococcal vaccination in Germany.

Authors:  Alexander Kuhlmann; Ulrike Theidel; Mathias W Pletz; J-Matthias Graf von der Schulenburg
Journal:  Health Econ Rev       Date:  2012-03-30

10.  Emerging pneumococcal carriage serotypes in a high-risk population receiving universal 7-valent pneumococcal conjugate vaccine and 23-valent polysaccharide vaccine since 2001.

Authors:  Amanda J Leach; Peter S Morris; Gabrielle B McCallum; Cate A Wilson; Liz Stubbs; Jemima Beissbarth; Susan Jacups; Kim Hare; Heidi C Smith-Vaughan
Journal:  BMC Infect Dis       Date:  2009-08-04       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.